EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study

Keith C Ferdinand iD, Fatima Rodriguez iD, Duccio Baldari iD, James Sullivan, Alexis Gutierrez, Subha Venkataraman, Kenny Onate-Quiroz iD, Hui Cao, Wenyue Zhu iD, Jing Wang iD, Michael D Shapiro iD

Circulation: Population Health and Outcomes · 09.11.2026

DOI: 10.1161/circoutcomes.126.014453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Population Health and Outcomes, online erschienen am 09.11.2026. Verfasst von Keith C Ferdinand und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tulane University School of Medicine, John W Deming Department of Medicine, Division of Cardiology, New Orleans, LA. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Gefördert von: Novartis.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Black and Hispanic individuals may experience a disproportionate burden of lipoprotein(a) [Lp(a)]-associated atherosclerotic cardiovascular disease (ASCVD) risk, and ASCVD-related mortality, yet remain underrepresented in cardiovascular (CV) clinical trials. Efficacy and safety data on Lp(a)-targeted therapies in these populations are limited.

Methods

Lp(a)FRONTIERS EXPANSION was a randomized, double-blind, phase 3b, placebo-controlled trial assessing the efficacy and safety of pelacarsen, an Lp(a)-targeted therapy, in US Black/African American and Hispanic participants with elevated Lp(a) (≥125 nmol/L) and ASCVD. Eligible adults were randomized 2:1 to monthly subcutaneous pelacarsen 80 mg or placebo for 12 months, followed by 16 weeks of safety follow-up. Enrollment spanned May 2024−March 2025. The primary endpoint was change in log-transformed Lp(a) from baseline at Week 52, analyzed using a mixed model for repeated measures.

Results

Overall, 423 participants were randomized, with 422 analyzed (282 to pelacarsen; 140 to placebo). The population comprised 64.5% (n=272) Black/non-Hispanic, 30.1% (n=127) nonBlack/Hispanic, and 5.5% (n=23) Black/Hispanic. Trial completion rates were 90.1% and 91.4% for pelacarsen and placebo groups, respectively; median (Q1, Q3) baseline Lp(a) levels were 232.70 nmol/L (165.80, 301.50) and 219.25 nmol/L (166.95, 293.65). Geometric mean ratio (GMR) of Lp(a) to baseline at Week 52 was 0.14 (95% CI: 0.12, 0.16) with pelacarsen and 0.98 (95% CI: 0.80, 1.20) with placebo; GMR between groups (pelacarsen/placebo) was 0.14 (95% CI: 0.11, 0.18; P

Autor:innen und Institutionen

  • Tulane University School of Medicine, John W Deming Department of Medicine, Division of Cardiology, New Orleans, LA.
  • Stanford University School of Medicine, Division of Cardiovascular Medicine, the Cardiovascular Institute, and the Center for Digital Health, Stanford, CA.
  • Cardiology Partners, Palm Beach County, FL.
  • Parkway Medical Center, Birmingham, AL.
  • Inpatient Research Clinic, LLC, Miami Lakes, FL.
  • Novartis Pharmaceuticals Corp, East Hanover, NJ.

ORCID-Profile: Keith C Ferdinand, Fatima Rodriguez, Duccio Baldari, Kenny Onate-Quiroz, Wenyue Zhu, Jing Wang, Michael D Shapiro

Förderung

  • Novartis

Zitieren

APA

Ferdinand, K. C., Rodriguez, F., Baldari, D., Sullivan, J., Gutierrez, A., Venkataraman, S., Onate-Quiroz, K., Cao, H., Zhu, W., Wang, J., & Shapiro, M. D. (2026). Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study. Circulation: Population Health and Outcomes. https://doi.org/10.1161/circoutcomes.126.014453

Vancouver

Ferdinand KC, Rodriguez F, Baldari D, Sullivan J, Gutierrez A, Venkataraman S, et al. Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study. Circulation: Population Health and Outcomes. 2026. doi:10.1161/circoutcomes.126.014453

BibTeX
@article{Ferdinand2026,
  author = {Ferdinand, Keith C and Rodriguez, Fatima and Baldari, Duccio and Sullivan, James and Gutierrez, Alexis and Venkataraman, Subha and Onate-Quiroz, Kenny and Cao, Hui and Zhu, Wenyue and Wang, Jing and Shapiro, Michael D},
  title = {Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease: The Randomized Controlled Lp(a)FRONTIERS EXPANSION Study},
  journal = {Circulation: Population Health and Outcomes},
  year = {2026},
  doi = {10.1161/circoutcomes.126.014453}
}
Kostenlos starten →